Blood test may help Fine-Tune heart drug dosing

NCT ID NCT07487714

ENROLLING_BY_INVITATION Disease control Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether measuring amiodarone levels in the blood helps doctors choose the right dose for people with paroxysmal atrial fibrillation (a type of irregular heartbeat). About 80 adults will receive different daily doses (100, 200, or 400 mg) and be monitored for three months. The goal is to see if this approach reduces the return of atrial fibrillation episodes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Amiodarone
What this could lead to: If successful, this could show that adjusting amiodarone dose based on blood levels improves control of atrial fibrillation with fewer side effects.
What could go wrong: This is a small, early-phase study (80 participants) and may not prove that blood monitoring is better than standard care. Amiodarone also has known risks like thyroid and lung problems.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PAROXYSMAL AF are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

atrial fibrillation paroxysmal atrial fibrillation

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PAROXYSMAL AF THERAPEUTIC DRUG MONITORING (TDM) TREATMENT DECISIONS

Contacts and locations

Locations

Kievskaya street 111a Cardiology research institute

Tomsk, 634012, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.